Indivior Share Discussion Threads

[citytrader66] 26/9/2018 16:56

16:19 Indivior PLC (INDV) Indivior Provides Business Update RNS

[shardview] 26/9/2018 16:43

HL say this closed up 4.8%%, but google has it down 10R%. Any ideas?

[7ran5ac710n] 24/9/2018 14:19

On a positive note, 20/9 RNS SL upped their stake by c.3% to c.10%Good news coming...?

[7ran5ac710n] 22/9/2018 06:48

1.2m buy @ 260.1 (16:35, 21/9)

[7ran5ac710n] 20/9/2018 10:16

Thought their no show was CBA but, admittedly, it was a little breezy...Thanks for the pointer - here's the link:http://www.indivior.com/wp-content/uploads/2018/09/FINAL-Updated-SUBLOCADE-KPIs-Morgan-Stanley.pdfAlways comforting to read 'risk of death' warnings in a business update.So, the pharmas dole out the excruciatingly addictive Papaver Somniferum based narcs, then 'invent' another drug to ween their addicts off of it... Pay both ways - commercial Paradise...But hey, what do I know? All IMHO.[Tranche investment @ 271p]

[gregmorg] 13/9/2018 17:13

Indivior posted some interesting slides which were to be presented at the aborted appearance at the Morgan Stanley farma conference.

[gregmorg] 10/9/2018 09:34

Interesting repayment of quite a chunk of debt. That is given that there has been no financial settlement as of yet with the US Justice Authorities- well, nothing announced. Hopes were raised for a near term announcement a few months back. Admittedly any settlement with the Justice is usually spread over a number of years but, even so, I wondered as to the signal it sent.

[naed] 21/8/2018 09:44

Very quite here......share price constantly loosing value?

[7ran5ac710n] 09/8/2018 10:32

RNS: Standard Life upping their stake to 7.09%...

[danieldanj] 31/7/2018 13:45

Indivior (INDV) News Out Just Now

[gregmorg] 31/7/2018 09:59

Yes this is better news.

I found yesterday's legal ruling, allowing Dr Redy's to expedite the hearing, was no surprise to certain legal professionals with one opinion stating there was no legal reason not to. That decision cast no view on the validity or otherwise of Indivior's patents. This latest ruling appears to be much more about upholding the validity of Indivior's patents, until proved otherwise, in a future Court hearing.

[grupo guitarlumber] 31/7/2018 09:12

31 July 2018

Indivior Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film Upheld

-Company will continue to vigorously defend our SUBOXONE(R) (buprenorphine and naloxone) Sublingual Film intellectual property -

Slough, UK, 31 July 2018 - Indivior PLC (LON: INDV) (Indivior or the Company) today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied Dr. Reddy's Laboratories' (DRL's) motion for a stay of the July 13, 2018 preliminary injunction (PI) previously granted by the District of New Jersey. The PI prohibits DRL from using, importing, selling, or offering to sell its generic buprenorphine/naloxone sublingual film product. DRL appealed this ruling, and filed emergency motions seeking to expedite the appeal of the PI, and to stay the PI pending a ruling on appeal. Today's ruling means that DRL continues to be prohibited from using, importing, selling, or offering to sell its generic buprenorphine/naloxone sublingual film product pending a favorable outcome for DRL on its appeal of the PI, or the District of New Jersey litigation related to U.S. Patent No. 9,931,305 (the '305 Patent); 9,687,454 (the '454 Patent); and 9,855,221 (the '221 Patent). The CAFC previously granted DRL's motion to expedite the appeal, and oral argument will be held the first week of October 2018.

Indivior will continue to vigorously defend its patent rights to SUBOXONE(R)Film, including opposing DRL's PI appeal, and continuing to pursue the appeal of the District of Delaware's noninfringement ruling related to U.S. Patent No. 8,603,514 (the '514 Patent), and the recently filed litigation asserting the '305, '454, and '221 Patents in the District of New Jersey.

[grupo guitarlumber] 31/7/2018 09:11

SURPRISED TOO, NO UPWARD MOMENTUM

PERHAPS ITS DUE TO END OF MONTH

[tsmith2] 31/7/2018 08:46

Surprised by lack of movement today

[gregmorg] 30/7/2018 09:50

The Dr Redy decision to expedite the Court hearing is, of course, purely legal. It has little to do with, and making no observations on, the actual validity of the Indivior patents..

[waldron] 30/7/2018 08:58

Oliver Haill
WebFG News
30 Jul, 2018 08:10 30 Jul, 2018 08:10
Indivior given October court date with Dr Reddy's, delays Perseris launch
Indivior
318.40
08:39:28 30/07/18
1.08%
3.40
FTSE 250
20,843.16
08:40:20 30/07/18
-0.12%
-25.78
FTSE 350
4,277.69
08:40:20 30/07/18
-0.25%
-10.91
FTSE All-Share
4,222.12
08:40:18 30/07/18
-0.25%
-10.52

Indivior's lawyers will be able to begin arguing the drug developer's case against Dr Reddy Laboratories in October, after the US appeals court agreed to speed up the process.

The FTSE 250-listed company also on Monday confirmed that its once-monthly treatment for schizophrenia in adults has been approved by the US drug regulator, but that it would delay the timing of the launch until it knew more about the Dr Reddy's case.

Dr Reddy's launched an appeal after Indivior was granted a preliminary injunction that prevented the generic drugmaker from selling its version of Indivior's Suboxone, a buprenorphine/naloxone sublingual film that is used as a treatment for opioid addiction.

The US Court of Appeals for the Federal Circuit has now granted-in-part a motion to expedite Dr Reddy's appeal of the preliminary injunction that prohibits its from using, importing, selling, or offering to sell its generic sublingual film, meaning oral argument are scheduled to be held during the first week of October.

Dr Reddy's appeal also requested a stay of the injunction but the CAFC has not yet ruled on this.

Although the US Food & Drug Administration over the weekend approved Perseris, a once-monthly injection to treat adult schizophrenia, Indivior said that, as it had indicated in its half-year results last week, it will hold back from launching this new treatment due to the uncertainty over the Dr Reddy's generic.

The company assured that would provide details of the "appropriate launch timing" for Perseris "as soon as reasonably practicable, but no later than its Q3 2018 results currently scheduled for November 1st".

Perseris contains risperidone, which is a well-established treatment for schizophrenia, but has been formulated by Indivior into an extended-release 'depot' delivery system that is delivered subcutaneously and remains sustained levels over the course of the month.

[tsmith2] 30/7/2018 08:08

Seems like it.expecting them to move up..

[steeplejack] 30/7/2018 07:32

"Motion to Expedite DRL's Appeal of Indivior's Preliminary Injunction Granted-in-Part"An offset to the approval of Perseris.Market makers could be in a quandary as how to open this one up.

[steeplejack] 29/7/2018 21:51

Depends on the whether the court dismisses the Dr Reddy appeal to lift the preliminary injunction. The company must be chuffed that it now has a drug that doesn't have generics breathing down its neck

[tsmith2] 29/7/2018 20:01

£3.5 open?

[gregmorg] 28/7/2018 14:16

Yes,Indeed good product news. So we expect an RNS first thing Monday